High rate of post‐therapeutic resistance after failure of macrolide–nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second‐line therapies in a randomized study

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Alimentary Pharmacology and Therapeutics

• Publication date

  2002-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1365-2036.2002.01173.xPMID 11860415
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized study of two “rescue” therapies for helicobacter pylori-infected patients after failure of standard triple therapies

  2001cited by this paper
• High-dose omeprazole/amoxicillin therapy versus quadruple therapy for treatment of Helicobacter pylori resistent against both metronidazole and clarthromycin — A prospective, randomized cross-over study

  2001cited by this paper
• Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole–amoxicillin–clarithromycin therapy

  2001cited by this paper
• A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole

  2001cited by this paper
• Second-line eradication of Helicobacter pylori after failure of an initial treatment: A randomized prospective study comparing four treatment strategies

  2001cited by this paper
• Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.

  2001cited by this paper
• Randomized study comparing omeprazole with ranitidine as anti‐secretory agents combined in quadruple second‐line Helicobacter pylori eradication regimens

  2000cited by this paper
• Guidelines on the management of H.pylori in primary care: development of an implementation strategy.

  2000cited by this paper
• Secondary Resistance Among 554 Isolates of Helicobacter pylori After Failure of Therapy

  2000cited by this paper
• Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta‐analysis of eradication of Helicobacter pylori

  2000cited by this paper
• Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study.

  2000cited by this paper
• Polymorphism in the Transmembrane Region of MICA Gene and Type 1 Diabetes

  2000cited by this paper
• Treatment failures and secondary resistance to antibiotics. A growing concern in Helicobacter pylori therapy.

  2000cited by this paper
• Regular review: treatment of Helicobacter pylori infection.

  2000cited by this paper
• Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate‐based therapies

  2000cited by this paper
• A systematic review of Helicobacter pylori eradication therapy—the impact of antimicrobial resistance on eradication rates

  1999cited by this paper
• Validity of a modified 13C-urea breath test for pre- and posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting

  1999cited by this paper
• Treatment after failure: the problem of “non-responders”

  1999cited by this paper
• Quadruple Therapy Is Effective for Eradicating Helicobacter pylori After Failure of Triple Proton‐Pump Inhibitor–Based Therapy: A Detailed, Prospective Analysis of 21 Consecutive Cases

  1999cited by this paper
• The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies.

  1999cited by this paper
• Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1‐week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer

  1999cited by this paper
• Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication.

  1999cited by this paper
• Treatment options for Helicobacter pylori infection when proton pump inhibitor‐based triple therapy fails in clinical practice

  1999cited by this paper
• A Practical Approach to Patients with Refractory Helicobacter pylori Infection, or Who Are Re-Infected After Standard Therapy

  1999cited by this paper
• The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis.

  1999cited by this paper
• Evaluation of short‐term low‐dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double‐blind, controlled study

  1998cited by this paper
• Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection

  1998cited by this paper
• Guidelines for the management of Helicobacter pylori infection

  1998cited by this paper
• Antibiotic resistance in Helicobacter pylori: implications for therapy.

  1998cited by this paper
• Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori.

  1998cited by this paper
• Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer

  1998cited by this paper
• Influence of metronidazole resistance on efficacy of quadruple therapy for Helicobacter pylori eradication

  1998cited by this paper
• Prevalence ofHelicobacter pylori resistance to several antimicrobial agents in a region of Germany

  1998cited by this paper
• Antibiotic resistance in Helicobacter pylori : Implications for therapy

  1998cited by this paper
• Treatment of Helicobacter pylori infection.

  1998cited by this paper
• Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials

  1998cited by this paper
• [Helicobacter pylori: pretherapeutic resistance status in Germany (Ruhr area)].

  1997cited by this paper
• The report of the Digestive Health InitiativeSM International Update Conference on Helicobacter pylori.

  1997cited by this paper
• Metronidazole Resistance Reduces Efficacy of Triple Therapy and Leads to Secondary Clarithromycin Resistance

  1997cited by this paper
• Doubling the omeprazole dose (40 mg b.d. vs. 20 mg b.d.) in dual therapy with amoxycillin increases the cure rate of Helicobacter pylori infection in duodenal ulcer patients

  1997cited by this paper
• Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group.

  1997cited by this paper
• Classification and Grading of Gastritis: The Updated Sydney System

  1997cited by this paper
• Validity of a novel biopsy urease test (HUT) and a simplified 13C-urea breath test for diagnosis of Helicobacter pylori infection and estimation of the severity of gastritis.

  1996cited by this paper
• Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994.

  1996cited by this paper

• The interval of rescue treatment does not affect the efficacy and safety of Helicobacter pylori eradication: A prospective multicenter observational study

  2025cites this paper
• NEW APPROACHES TO OVERCOMING ANTIBIOTIC RESISTANCE

  2024cites this paper
• Optimization of Minocycline‐Containing Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Real‐World Evidence Study

  2024cites this paper
• ANTIBIOTIC RESISTANCE, RATIONAL ANTIBIOTIC THERAPY AND PROBIOTICS IN THE COMPLEX TREATMENT OF PERITONITIS

  2023cites this paper
• Egg yolk antibody combined with bismuth-based quadruple therapy in Helicobacter pylori infection rescue treatment: a single-center, randomized, controlled study

  2023cites this paper
• Second line therapy for Helicobacter pylori eradication: state of art.

  2022cites this paper
• High-dose dual therapy is effective as first-line treatment for Helicobacter pylori infection.

  2020cites this paper
• High-Dose Dual Therapy versus Triple Therapy for Treatment of H. Pylori Infection: A Parallel Randomized Study

  2020cites this paper
• High‐dose proton pump inhibitor and amoxicillin dual therapy with or without bismuth for 14 days as rescue therapies after Helicobacter pylori treatment failure

  2020cites this paper
• Systematic review: Would susceptibility‐guided treatment achieve acceptable cure rates for second‐line Helicobacter pylori therapy as currently practiced?

  2019cites this paper
• Treatment of Helicobacter pylori in Special Patient Populations

  2019cites this paper
• Helicobacter pylori eradication rates with concomitant and tailored therapy based on 23S rRNA point mutation: A multicenter randomized controlled trial

  2019cites this paper
• THE FREQUENCY OF DETECTION OF THE ACTIVE FORM OF HELICOBACTER PYLORI INFECTION IN PATIENTS WITH CHRONIC NON-ATROPHIC GASTRITIS WITH BILIARY DYSKINESIA ON THE HYPOTONIC HYPOKINETIC TYPE AND WITH PRESERVED FUNCTION OF THE GALL BLADDER

  2019cites this paper
• Helicobacter pylori therapy and clinical perspective.

  2018cites this paper
• ACG Clinical Guideline: Treatment of Helicobacter pylori Infection

  2017cites this paper
• deal treatment for Helicobacter pylori : A systematic review

  2017cites this paper
• Ideal treatment for Helicobacter pylori : A systematic review

  2017cites this paper
• Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy

  2016cites this paper
• Bismuth-Containing Therapy for Helicobacter pylori Eradication

  2016cites this paper
• Ideal treatment for Helicobacter pylori : A systematic review 29

  2015cites this paper
• High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection.

  2015cites this paper
• Helicobacter pylori — Current Therapy and Future Therapeutic Strategies

  2014cites this paper
• Ideal treatment for Helicobacter pylori: A systematic review

  2014cites this paper
• Tratamiento ideal del Helicobacter pylori: una revisión sistemática

  2014cites this paper
• Rifabutin-based High-dose Proton-pump Inhibitor and Amoxicillin Triple Regimen as the Rescue treatment for Helicobacter pylori

  2014cites this paper
• Helicobacter pylori antimicrobial resistance rates in the central region of Portugal.

  2014cites this paper
• Current options for the treatment of Helicobacter pylori

  2013cites this paper
• Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study

  2013cites this paper
• Rescue Therapy for Helicobacter pylori Infection 2012

  2012cites this paper
• A modified Bismuth‐Containing Quadruple Therapy Including a Short Course of Furazolidone for Helicobacter pylori Eradication After Sequential Therapy Failure

  2012cites this paper
• ЯЗВЕННАЯ БОЛЕЗНЬ: АКТУАЛЬНЫЕ ПРОБЛЕМЫ ЭТИОЛОГИИ, ПАТОГЕНЕЗА, ДИФФЕРЕНЦИРОВАННОГО ЛЕЧЕНИЯ

  2012cites this paper
• Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients.

  2012cites this paper
• High‐dose rabeprazole–amoxicillin dual therapy and rabeprazole triple therapy with amoxicillin and levofloxacin for 2 weeks as first and second line rescue therapies for Helicobacter pylori treatment failures

  2012cites this paper
• Role of Omeprazole Dosage and Cytochrome P450 2C19 Genotype in Patients Receiving Omeprazole‐Amoxicillin Dual Therapy for Helicobacter pylori Eradication

  2011cites this paper
• Review article: non‐bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori

  2011cites this paper
• The efficacy of a 1-week triple therapy for eradication of Helicobacter pylori infection in children.

  2011cites this paper
• Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection.

  2010cites this paper
• CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection

  2010cites this paper
• Ulcer Disease and Helicobacter pylori Infection: Etiology and Treatment

  2010cites this paper
• Treatment of Helicobacter pylori infections: Mitigating factors and prospective natural remedies

  2010cites this paper
• Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin.

  2010cites this paper
• Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis

  2010cites this paper
• The sequential therapy regimen for Helicobacter pylori eradication

  2010cites this paper
• Sequential Metronidazole‐Furazolidone or Clarithromycin‐Furazolidone Compared to Clarithromycin‐Based Quadruple Regimens for the Eradication of Helicobacter pylori in Peptic Ulcer Disease: A Double‐Blind Randomized Controlled Trial

  2010cites this paper
• Clinical Practice: Diagnosis and Evaluation of Dyspepsia

  2010cites this paper
• Sequential Therapy for Helicobacter pylori Eradication: A Critical Review

  2010cites this paper
• Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States

  2010cites this paper
• Review: Second-line rescue therapy of Helicobacter pylori infection

  2009cites this paper
• Helicobacter pylori infection.

  2009influential citation
• Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial.

  2009cites this paper
• Prevalence of multidrug-resistant Helicobacter pylori in Bulgaria.

  2009cites this paper
• Efficacy of a 7-day course of furazolidone, levofloxacin, and lansoprazole after failed Helicobacter pylori eradication

  2009cites this paper
• Short-term celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model.

  2009cites this paper
• "Rescue" regimens after Helicobacter pylori treatment failure.

  2008cites this paper
• Prevalence and evolution of Helicobacter pylori resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods.

  2008cites this paper
• Short-term triple therapy with azithromycin for Helicobacter pylori eradication: Low cost, high compliance, but low efficacy

  2008cites this paper
• Triple therapy-based targeted nanoparticles for the treatment of Helicobacter pylori.

  2008cites this paper
• Helicobacter pylori eradication therapy: indications, efficacy and safety

  2008cites this paper
• "Rescue" regimens after Helicobacter pylori treatment

  2008cites this paper
• Triple therapy-based targeted nanoparticles for the treatment of Helicobacter pylori

  2008cites this paper
• Treatment of Helicobacter pylori.

  2007cites this paper
• Levofloxacin‐Containing Triple Therapy to Eradicate the Persistent H. pylori after a Failed Conventional Triple Therapy

  2007cites this paper
• Esomeprazole-Based 1-Week Triple Therapy Directed by Susceptibility Testing for Eradication of Helicobacter pylori Infection in Children

  2006influential citation
• Evidence-based gastroenterology and hepatology, second edition

  2006cites this paper
• Efficacy and Safety of Rabeprazole, Amoxicillin, and Gatifloxacin After Treatment Failure of Initial Helicobacter pylori Eradication

  2006cites this paper
• Efficacy and safety of rifabutin‐containing ‘rescue therapy’ for resistant Helicobacter pylori infection

  2006cites this paper
• Ulkuskrankheit

  2006cites this paper
• ‘Rescue’ Therapies for the Management of Helicobacter pylori Infection

  2006cites this paper
• [Peptic ulcer disease. Clinical evaluation in 2006].

  2006cites this paper
• Pretreatment with Lactobacillus- and Bifidobacterium-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy.

  2006cites this paper
• Randomized trial of rifabutin‐based triple therapy and high‐dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin

  2006cites this paper
• 7‐Day Triple Therapy of Helicobacter pylori Infection with Levofloxacin, Amoxicillin, and High‐Dose Esomeprazole in Patients with Known Antimicrobial Sensitivity

  2006cites this paper
• Antibacterial resistance in Helicobacter pylori strains isolated from Bulgarian children and adult patients over 9 years.

  2006cites this paper
• Third-line rescue therapy for Helicobacter pylori infection.

  2006cites this paper
• Therapie der Helicobacter-pylori- Infektion

  2005cites this paper
• Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication

  2005cites this paper
• Helicobacter pylori“Rescue” Therapy After Failure of Two Eradication Treatments

  2005cites this paper
• Helicobacter pylori first‐line treatment and rescue options in patients allergic to penicillin

  2005cites this paper
• Systematic Review and Meta‐analysis: Proton Pump Inhibitor vs. Ranitidine Bismuth Citrate Plus Two Antibiotics in Helicobacter pylori Eradication

  2005cites this paper
• Treatment of H. pylori infection: a review.

  2005cites this paper
• High Eradication Rates of Helicobacter pylori Infection with First- and Second-Line Combination of Esomeprazole, Tetracycline, and Metronidazole in Patients Allergic to Penicillin

  2005cites this paper
• Nuevo esquema ultracorto para erradicar la infección por Helicobacter pylori utilizando tetraciclina, furazolidona y subcitrato de bismuto coloidal en pacientes dispépticos con o sin úlcera péptica en el Hospital Nacional Cayetano Heredia

  2005cites this paper
• Eradication of Helicobacter pylori: a clinical update.

  2004cites this paper
• Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts.

  2004cites this paper
• [Helicobacter pylori infection and antimicrobial agents resistance].

  2004cites this paper
• Pharmacotherapy of Helicobacter pylori-associated gastritis

  2004cites this paper
• Infection Helicobacter pylori et rsistance aux antibiotiques

  2004cites this paper
• H pylori antibiotic resistance: prevalence, importance, and advances in testing

  2004cites this paper
• Reliable detection of macrolide-resistant Helicobacter pylori via fluorescence in situ hybridization in formalin-fixed tissue

  2004cites this paper
• 39 sensitivities of Helicobacter pylori vary at different gastric mucosal sites

  2003cites this paper
• Quel traitement peut-on proposer après un échec d'éradication de Helicobacter pylori ?

  2003cites this paper
• Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts

  2003cites this paper
• A Prospective, Randomized Study of Quadruple Therapy and High‐Dose Dual Therapy for Treatment of Helicobacter Pylori Resistant to Both Metronidazole and Clarithromycin

  2003cites this paper
• High‐dose rabeprazole–amoxicillin versus rabeprazole–amoxicillin–metronidazole as second‐line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection

  2003cites this paper
• Is antimicrobial susceptibility testing necessary before second‐line treatment for Helicobacter pylori infection?

  2003cites this paper
• Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori

  2003cites this paper
• Treatment of helicobacter pylori eradication failures

  2003cites this paper
• [How to treat after Helicobacter pylori eradication failure?].

  2003cites this paper
• Antibiotic sensitivities of Helicobacter pylori vary at different gastric mucosal sites

  2003cites this paper
• Attitude facing a patient suffering from Helicobacter pylori infection resistant to a triple therapy.

  2003cites this paper